LoginSignup
Bridgebio Pharma logo

Bridgebio Pharma Stock

StockStock
ISIN: US10806X1028
Ticker: BBIO
US10806X1028
BBIO

Price

Frequently asked questions

What is Bridgebio Pharma's market capitalization?

The market capitalization of Bridgebio Pharma is $4.69B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Bridgebio Pharma?

Bridgebio Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.412. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Bridgebio Pharma's stock?

Currently, 13 analysts cover Bridgebio Pharma's stock, with a consensus target price of $50.42. Analyst ratings provide insights into the stock's expected performance.

What is Bridgebio Pharma's revenue over the trailing twelve months?

Over the trailing twelve months, Bridgebio Pharma reported a revenue of $217.77M.

What is the EBITDA for Bridgebio Pharma?

Bridgebio Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$526.40M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Bridgebio Pharma?

Bridgebio Pharma has a free cash flow of -$456.33M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Bridgebio Pharma's stock?

The 5-year beta for Bridgebio Pharma is 1.05. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Bridgebio Pharma have, and what sector and industry does it belong to?

Bridgebio Pharma employs approximately 550 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Bridgebio Pharma's shares?

The free float of Bridgebio Pharma is 152.31M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $4.69B

5Y beta

 1.05

EPS (TTM)

 -$2.412

Free Float

 152.31M

Revenue (TTM)

 $217.77M

EBITDA (TTM)

 -$526.40M

Free Cashflow (TTM)

 -$456.33M

Pricing

52W span
$21.62$44.32

Analyst Ratings

The price target is $50.42 and the stock is covered by 13 analysts.

Buy

12

Hold

1

Sell

0

Information

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

550

Biotechnology & Drugs

Health Care

Identifier

ISIN

US10806X1028

Primary Ticker

BBIO

Knockouts

Join the conversation
Sign upLogin